№ lp_1_2_16240
File format: docx
Character count: 1954
File size: 64 KB
Note:
Year
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Version:
Draft 2.0 | Effective: //_____ | Owner: Director of Special Education / 504 Coordinator | Approved by: __________________________
Year:
Draft 2.0
Region / City:
Midland ISD
Subject:
Special Education, Section 504
Document Type:
Manual
Organization / Institution:
Midland Independent School District
Author:
Director of Special Education
Target Audience:
School staff, administrators, special education professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Contextual description:
A procedural manual for special education and Section 504 practices in Midland ISD, providing detailed operational steps for child find, referrals, evaluations, and compliance with federal and state regulations.
Year:
2026
Region / City:
European Union
Subject:
Pharmaceutical Product Information
Document Type:
Pharmaceutical Summary
Organization:
European Medicines Agency
Author:
European Medicines Agency
Target Audience:
Healthcare professionals
Period of validity:
Ongoing
Approval Date:
2026
Date of Modifications:
2026
Contextual Description:
The document outlines the product characteristics, indications, dosage, administration guidelines, and precautions for the pharmaceutical product Tysabri, as approved by the European Medicines Agency.
Year:
2023
Region / city:
Australia
Topic:
Vedolizumab submission for chronic pouchitis treatment
Document type:
Submission for listing of medicinal product
Agency:
Therapeutic Goods Administration (TGA)
Author:
Takeda Pharmaceuticals Australia Pty. Ltd.
Target audience:
Healthcare professionals, regulatory authorities
Effective period:
From 29 June 2023
Approval date:
29 June 2023
Modification date:
N/A
Note:
Year
Organization / Institution:
National Oceanic and Atmospheric Administration (NOAA)
DUPILUMAB, 300 mg in 2 mL single use pre-filled syringe, Dupixent®, Sanofi-Aventis Australia Pty Ltd
Year:
2023
Region / City:
Australia
Subject:
Atopic dermatitis treatment
Document type:
Application resubmission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target audience:
Healthcare professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Year:
2003
Region / City:
United States
Topic:
Insurance Verification, Billing Systems, Healthcare IT
Document Type:
Technical Manual / Security Guide
Organization:
Department of Veterans Affairs, Office of Information and Technology
Author:
MCCF EDI TAS eInsurance
Intended Audience:
Technical personnel for installation and maintenance of the software
Effective Period:
Ongoing updates
Approval Date:
September 2003
Revision Date:
August 2022
Year:
2026
Region / City:
Fort Collins, CO
Topic:
Parking System Consulting
Document Type:
Request for Quotation (RFQ)
Organization:
City of Fort Collins
Author:
Purchasing Division
Target Audience:
Professionals in the parking and urban planning sectors
Effective Period:
February 2026
Approval Date:
February 2026
Amendment Date:
Not specified
Type of document:
Pharmaceutical Benefits Advisory Committee (PBAC) submission and assessment report
Medicine:
Aripiprazole long-acting injectable (AOM)
Dosage forms/strengths:
Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe; Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe
Brand:
Abilify Maintena
Sponsor:
Lundbeck Australia Pty Ltd
Purpose of submission:
Request for General Schedule Authority Required (STREAMLINED) PBS listing of AOM pre-filled syringe dose form
Indication:
Treatment of schizophrenia
Comparator:
AOM modified release injection vial kit (therapeutic vial kits)
Regulatory status:
TGA registered 7 May 2018 for acute and maintenance treatment of schizophrenia in adults and maintenance treatment of bipolar I disorder (monotherapy)
Previous PBAC consideration:
400 mg AOM PFS recommended July 2018; recommendation rescinded March 2023
Pricing basis:
Cost-minimisation versus AOM vial kit with equivalent pricing (no price premium)
Price levels referenced:
DPMQ, PTP, AEMP (current as of 1 June 2025)
Estimated PBS usage:
400,000 to <500,000 scripts over first six years (Year 1 10,000–<20,000; Year 6 100,457)
Indication listing conditions:
Authority Required (Streamlined); prescriber types include medical practitioners and nurse practitioners; general schedule (Code GE)
Year:
2022
Region / City:
Australia
Subject:
Pharmacology, Pharmaceutical Benefits Scheme (PBS)
Document Type:
Submission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval Date:
3 June 2022
Date of Changes:
Not specified
Contextual Description:
A regulatory submission detailing the request for listing of dupilumab in new forms for treating severe atopic dermatitis and uncontrolled severe asthma in pediatric patients under the PBS.
Note:
Year
Agency / Institution:
Department of Professional and Financial Regulation, Bureau of Consumer Credit Protection
Note:
Year
Background:
The submission requested a General Schedule Authority Required (Telephone/Online) listing of a new form of adrenaline (epinephrine) acid tartrate 150 micrograms/0.15 mL autoinjector (AI) (Jext® Junior (Jr)) and 300 micrograms/0.3 mL AI (Jext®) under the same circumstances as the currently listed adrenaline (epinephrine) 150 microgram/0.3 mL AI (EpiPen® Jr and Anapen® Jr 150) and 300 microgram/0.3 mL AI (EpiPen® and Anapen® 300).
Year:
2021
Region / City:
Australia
Topic:
Atopic dermatitis treatment, medication submission
Document Type:
Submission report
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Sanofi-Aventis
Target Audience:
Medical professionals, regulatory authorities
Action Period:
Ongoing treatment evaluation
Approval Date:
17 August 2021
Modification Date:
Not specified
Background:
Dupilumab registration history
Clinical Claim:
Dupilumab has superior efficacy compared to standard care for children with severe atopic dermatitis
Episodicity:
Chronic
Severity:
Severe
Condition:
Atopic dermatitis
PBS Indication:
Chronic severe atopic dermatitis
Prescriber Type:
Medical practitioners, dermatologists, clinical immunologists
Treatment Phase:
Initial, continuing
Population Criteria:
Children aged 6 to 11 years, specific weight ranges
Comparator:
Placebo
Outcomes:
EASI-75, IGA 0 or 1 at Week 16, improvement in itch score
Dosing:
Tiered by body weight
Cost:
$1,754.28–$3,380.91
Price:
Published price for maximum quantity
Form:
Pre-filled syringe
Medical Information:
Dupilumab 300 mg/2 mL, 200 mg/1.14 mL
Note:
Comparator
Standard of care (Placebo)
Source:
PBAC submission
Year:
2023
Region / City:
Northwestern
Topic:
Sports, Basketball
Document Type:
Program Guidelines
Organization:
Northwestern Wildcat Boys Basketball Team
Author:
Coach Redman
Target Audience:
Basketball players
Period of Validity:
April 1 - November 1
Approval Date:
Not specified
Date of Modifications:
Not specified
Year:
2022
Region / city:
Region 6
Topic:
Healthcare, Emergency Preparedness
Document type:
Situation Manual
Organization / institution:
U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR)
Author:
ASPR NHPP Design Team
Target audience:
Healthcare professionals, emergency preparedness and response teams, exercise participants
Period of validity:
October 27, 2022
Approval date:
October 27, 2022
Date of amendments:
N/A
Contextual description:
A comprehensive manual outlining procedures, objectives, and roles for participants in a medical response and surge exercise organized by ASPR.
Year:
2024
Region / City:
Connecticut
Subject:
Scholarship application rules
Document Type:
Scholarship application form
Organization:
Connecticut Junior Women, Inc.
Author:
Not specified
Target Audience:
Women involved with volunteer activities
Effective Period:
2024
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / City:
Connecticut
Topic:
Early Childhood Intervention
Document Type:
Report
Agency:
Office of Early Childhood (OEC)
Author:
Office of Early Childhood (OEC)
Target Audience:
State and local education agencies, early childhood service providers
Effective Period:
FFY 2023
Approval Date:
N/A
Amendment Date:
N/A
Plan Effective Date:
January 1, 2022
Plan last modified on:
January 1, 2025
Employer:
[Company Name]
Employee Contributions:
Employees must contribute [0.5%] of their wages
Coverage:
All employees working in Connecticut
Leave Compensation Duration:
Maximum 12 weeks in a 12-month period
Paid Leave Compensation Start Date:
No waiting period
Leaves that Qualify for Compensation:
Serious health condition, birth of a child, family care, military exigency, family violence or sexual assault
Employer Records Retention:
Minimum three years after plan termination
Employee Right to Review:
Available upon request
Plan Termination:
Does not affect eligibility for benefits from approved leaves
Year:
Current
Region / City:
Various US states and districts
Topic:
State Education and Higher Education Agencies
Document Type:
Official State Agency Information
Organization / Institution:
Various US state and district education agencies
Author:
N/A
Target Audience:
Students, Educational Institutions
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A